1. Home
  2. CTNM vs UHT Comparison

CTNM vs UHT Comparison

Compare CTNM & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$17.05

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Logo Universal Health Realty Income Trust

UHT

Universal Health Realty Income Trust

N/A

Current Price

$41.46

Market Cap

628.5M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
CTNM
UHT
Founded
2009
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
550.7M
628.5M
IPO Year
2024
1995

Fundamental Metrics

Financial Performance
Metric
CTNM
UHT
Price
$17.05
$41.46
Analyst Decision
Buy
Hold
Analyst Count
4
1
Target Price
$19.00
$43.00
AVG Volume (30 Days)
541.9K
88.5K
Earning Date
05-13-2026
04-27-2026
Dividend Yield
N/A
7.33%
EPS Growth
0.46
N/A
EPS
N/A
0.79
Revenue
N/A
$99,190,000.00
Revenue This Year
N/A
$2.12
Revenue Next Year
N/A
$2.94
P/E Ratio
N/A
$52.43
Revenue Growth
N/A
0.18
52 Week Low
$8.60
$35.26
52 Week High
$17.51
$46.30

Technical Indicators

Market Signals
Indicator
CTNM
UHT
Relative Strength Index (RSI) 63.03 47.24
Support Level $13.65 $39.63
Resistance Level N/A $43.06
Average True Range (ATR) 0.98 0.87
MACD 0.18 0.08
Stochastic Oscillator 88.27 47.04

Price Performance

Historical Comparison
CTNM
UHT

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

Share on Social Networks: